GC
ENTA icon

Guggenheim Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

Guggenheim Capital’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,692
Closed -$437K – 2138
2021
Q3 		$437K Buy
+7,692
New +$380K ﹤0.01% 1798
2018
Q4 		– Sell
-13,699
Closed -$1.17M – 2221
2018
Q3 		$1.17M Buy
13,699
+2,576
+23% +$258K 0.01% 1531
2018
Q2 		$1.29M Sell
11,123
-42,096
-79% -$4.2M 0.01% 1490
2018
Q1 		$4.31M Buy
53,219
+43
+0.1% +$3.31K 0.01% 1106
2017
Q4 		$3.12M Buy
53,176
+25,413
+92% +$1.27M 0.01% 1329
2017
Q3 		$1.3M Buy
27,763
+1,605
+6% +$64.5K ﹤0.01% 1940
2017
Q2 		$942K Sell
26,158
-1,402
-5% -$44.8K ﹤0.01% 2109
2017
Q1 		$848K Sell
27,560
-2,990
-10% -$93.1K ﹤0.01% 2183
2016
Q4 		$1.02M Buy
+30,550
New +$876K ﹤0.01% 2127
2016
Q3 		– Sell
-36,718
Closed -$809K – 2895
2016
Q2 		$809K Buy
36,718
+5,118
+16% +$134K ﹤0.01% 2178
2016
Q1 		$928K Buy
31,600
+11,919
+61% +$332K ﹤0.01% 2102
2015
Q4 		$650K Sell
19,681
-31,122
-61% -$1.01M ﹤0.01% 2315
2015
Q3 		$1.84M Buy
50,803
+12,740
+33% +$547K 0.01% 1654
2015
Q2 		$1.71M Sell
38,063
-7,132
-16% -$277K ﹤0.01% 1891
2015
Q1 		$1.38M Buy
45,195
+4,869
+12% +$189K ﹤0.01% 2068
2014
Q4 		$2.05M Sell
40,326
-165,062
-80% -$7.39M 0.01% 1720
2014
Q3 		$8.13M Buy
205,388
+192,691
+1,518% +$7.68M 0.02% 979
2014
Q2 		$562K Buy
+12,697
New +$484K ﹤0.01% 2549

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Guggenheim Capital's ENTA Position: Q4 2021 in Review

Guggenheim Capital sold out of Enanta Pharmaceuticals (ENTA) in Q4 2021, closing a stake of 7,692 shares — an estimated $437K sold.

Guggenheim Capital first reported a position in ENTA in Q2 2014 and held it in 18 quarters. The position peaked at $8.13M in Q3 2014. 179 funds tracked by Wall St. Rank hold ENTA as of Q4 2021.

  • Guggenheim Capital reported no remaining Enanta Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Guggenheim Capital sold 7,692 Enanta Pharmaceuticals shares in Q4 2021, an estimated $437K.
  • Guggenheim Capital first reported a position in Enanta Pharmaceuticals in Q2 2014 and held it in 18 quarters.
  • Guggenheim Capital's Enanta Pharmaceuticals position peaked at $8.13M in Q3 2014.
  • 179 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2021.

Based on Guggenheim Capital's 13F filing for Q4 2021, filed 14 Feb 2022.